1/23
03:36 pm
avr
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well [Yahoo! Finance]
Low
Report
Retail investors who hold 25% of Anteris Technologies Global Corp. (ASX:AVR) gained 41%, institutions profited as well [Yahoo! Finance]
1/23
10:14 am
avr
Anteris Technologies Global (NASDAQ:AVR) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
Medium
Report
Anteris Technologies Global (NASDAQ:AVR) had its "buy" rating reaffirmed by analysts at Lake Street Capital.
1/22
04:02 pm
avr
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
Medium
Report
Anteris Announces Strategic Investment from Medtronic to Continue Advancing TAVR in $320 Million Aggregate Capital Raises
1/22
04:01 pm
avr
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
Low
Report
Anteris Technologies Global Corp. Announces Closing of $230 Million Public Offering of Common Stock
1/22
12:10 am
avr
Medtronic to buy up to $90M stake in heart valve developer Anteris [Yahoo! Finance]
Medium
Report
Medtronic to buy up to $90M stake in heart valve developer Anteris [Yahoo! Finance]
1/20
10:53 pm
avr
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
High
Report
Anteris Technologies Global Corp. Announces Pricing of $200 Million Public Offering
1/20
04:01 pm
avr
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
Medium
Report
Anteris Technologies Global Corp. Announces Proposed $200 Million Public Offering of Common Stock and Strategic Investment from Medtronic
11/26
02:01 pm
avr
Anteris Technologies Global (NASDAQ:AVR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Anteris Technologies Global (NASDAQ:AVR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/17
06:00 am
avr
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
Medium
Report
Anteris Technologies Presents Data from 100 DurAVR® THV Patients at PCR London Valves
11/12
05:52 pm
avr
Anteris Announces Results for the Third Quarter of 2025
Medium
Report
Anteris Announces Results for the Third Quarter of 2025
11/3
07:00 am
avr
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Medium
Report
FDA Approves Anteris’s DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)